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Highlights  
- The hypothalamic neuropeptide oxytocin acts as an anorexigenic signal. 
- Intranasal oxytocin delivery curbs food intake in healthy and obese individuals. 
- Possible links to oxytocin’s psychosocial function are discussed. 
- Does oxytocin hold some clinical potential as an appetite-reducing drug? 
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Abstract 
In the face of the alarming prevalence of obesity and its associated metabolic impairments, it 
is of high basic and clinical interest to reach a complete understanding of the central nervous 
pathways that establish metabolic control. In recent years, the hypothalamic neuropeptide 
oxytocin, which is primarily known for its involvement in psychosocial processes and 
reproductive behavior, has received increasing attention as a modulator of metabolic 
function. Oxytocin administration to the brain of normal-weight animals, but also animals 
with diet-induced or genetically engineered obesity reduces food intake and body weight, and 
can also increase energy expenditure. Up to now, only a handful of studies in humans have 
investigated oxytocin’s contribution to the regulation of eating behavior. Relying on the 
intranasal pathway of oxytocin administration, which is a non-invasive strategy to target 
central nervous oxytocin receptors, these experiments have yielded some promising first 
results. In normal-weight and obese individuals, intranasal oxytocin acutely limits meal 
intake and the consumption of palatable snacks. It is still unclear to which extent – or if at all 
– such metabolic effects of oxytocin in humans are conveyed or modulated by oxytocin’s 
impact on cognitive processes, in particular on psychosocial function. We shortly summarize 
the current literature on oxytocin’s involvement in food intake and metabolic control, ponder 
potential links to social and cognitive processes, and address future perspectives as well as 
limitations of oxytocin administration in experimental and clinical contexts.  
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1. Introduction 1 
The hypothalamic neuropeptide oxytocin, besides its physiological function in parturition and 2 
lactation, is primarily known for its role in psychosocial and affective processing, e.g., in 3 
bonding behavior, emotion regulation, and sexual function [1–4]. Oxytocin is released into 4 
the circulation by axonal terminals in the posterior pituitary and, in addition, acts directly on 5 
central nervous receptors. Interestingly, oxytocin is produced in hypothalamic regions that 6 
also regulate appetite and metabolism and are targets of appetite-regulating hormones like 7 
leptin, cholecystokinin (CCK) and ghrelin [5,6]. Important insights into the role of oxytocin 8 
in the central nervous regulation of metabolic functions have been obtained in animal 9 
experiments (e.g., [7–9]; for review see [10,11]) which indicate that oxytocin contributes to 10 
the control of food intake, energy expenditure and glucose homeostasis [12,13]. In recent 11 
years, first experiments to investigate respective effects in the human organism have been 12 
performed, primarily relying on the intranasal pathway of neuropeptide delivery to the brain. 13 
Intranasal administration of oxytocin in humans has been repeatedly shown to inhibit eating 14 
behavior driven by hunger due to energy depletion as well as by more reward-related, 15 
‘hedonic’ factors associated with food intake [14–16]. This short review summarizes the 16 
effects of oxytocin on ingestive behavior in healthy humans and subjects with obesity or 17 
eating disorders, with the aim of providing an update on current research and future 18 
directions, and looks at possible links between oxytocin’s eating-related function and its role 19 
in psychosocial regulation (see Figure 1 for an overview of oxytocin effects).   20 
 21 
2. The neuropeptide oxytocin 22 
Oxytocin is a nine-amino acid neuropeptide hormone that is predominantly produced in two 23 
hypothalamic regions, the paraventricular nucleus (PVN) and the supraoptic nucleus [17]. 24 
PVN oxytocin neurons project to the pituitary gland (about 40%) and a number of brain areas 25 
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including the brainstem. Around ten percent of PVN neurons project to three core areas of the 26 
brainstem that play an important role in the regulation of food intake: nucleus tractus 27 
solitarius, dorsal motor nucleus of the vagus nerve (DMNV), and area postrema [18,19]. 28 
Oxytocin in addition is active in brain areas of relevance for reward- and eating-related 29 
behavior such as the ventral tegmental area (VTA), nucleus accumbens (NAcc), and nucleus 30 
stria terminalis [20]. It is assumed that only a small ratio of oxytocin released into the 31 
periphery via the posterior pituitary passes the blood-brain barrier to re-enter the brain [21], 32 
which might explain why oxytocin concentrations are up to 1000 times higher in the brain 33 
than in the blood. In conjunction with the observation that the half-life of the peptide in the 34 
central nervous system (CNS) is over three times longer than in the periphery (19 vs. 6 35 
minutes) [22,23], this pattern furthermore points to the specific relevance of the hormone for 36 
central nervous functions [24]. 37 
The role of oxytocin in the periphery and in particular in the female reproductive 38 
system is well established, first of all with regard to fertilization and parturition. During 39 
pregnancy, the uterus increases its oxytocin sensitivity before giving birth, and receptor 40 
density increases during labor [25]. The human ovary also expresses oxytocin receptors 41 
(OXTR), and oxytocin possibly affects the fertilization process and the very early 42 
development of the embryo [26]. The most prominent role of oxytocin in humans concerns 43 
lactation. The infant triggers secretion of the peptide by sucking on the mother’s nipple, 44 
which stimulates additional milk ejection. The male reproductive system has also been 45 
observed to be oxytocin-sensitive [27]. 46 
The G-protein coupled OXTR [28] can be found in a wide range of brain regions (see 47 
ref. [27,29] for review), e.g., in hypothalamus, amygdala, anterior cingulate cortex, olfactory 48 
nucleus, and in limbic areas [30]. Moreover, oxytocin interacts with other neurotransmitters 49 
to influence brain function. It has been suggested that serotonin increases oxytocin 50 
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concentrations [31] and that dopamine interacts with oxytocin [32] to modulate activity of the 51 
brain’s reward circuitry [32,33] (see also chapter 4.2 of this review). The latter interaction has 52 
been assumed to be of relevance for behavioral disorders such as sexual dysfunction, autism, 53 
depression, but also eating disorders (see ref. [34] for further reading). In addition to its 54 
expression in the brain, oxytocin is expressed in myenteric and submucous ganglia and nerve 55 
fibres of the human gastrointestinal tract [35], with potential consequences for eating 56 
behavior and metabolism.  57 
A suitable way to study the contribution of (neuro)peptidergic messengers to human 58 
brain function is the intranasal route of administration, which largely bypasses the blood-59 
brain barrier (BBB) and delivers neuropeptides directly to the CNS. In humans, intranasally 60 
administered peptides have been found to reach the CNS within 45 min after delivery [36]. 61 
Since intra-neuronal transport of neuropeptides from the nasal mucosa to the olfactory bulb 62 
normally takes several hours [37], it is assumed that intranasally administered neuropeptides 63 
travel to the CNS via extra-neuronal pathways, bypassing the BBB paracellularly by 64 
diffusing into the subarachnoidal space across the olfactory epithelia and through intercellular 65 
clefts between sustentacular cells and olfactory neurons [38]. Passage of intranasally 66 
delivered peptides to the brain may also be established along cranial and trigeminal nerve 67 
branches [39]. Most recently, bulk flow within the perivascular space of cerebral blood 68 
vessels has been identified as another transport mechanism after intranasal administration 69 
[40]. Research relying on nasal spray application (mainly of 24-30 IU) of oxytocin indicates 70 
that the concentration of the peptide increases in both saliva and peripheral blood, with peak 71 
plasma concentrations at 10-40 min, or even 90 min following intranasal application [41–43]. 72 
Recent experiments by Striepens and colleagues [44] suggest that plasma oxytocin 73 
concentrations peak 15 min after intransal adminstration (24 IU) while cerebrospinal fluid 74 
oxytocin concentrations reach their maximum up to 75 min post administration, so that the 75 
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strongest brain effect of intranasal oxytocin might emerge around 60 min after 76 
administration. Intranasally administered oxytocin has been assumed to travel along the 77 
olfactory system to amygdaloid nucei, which are directly connected to the hypothalamus. 78 
This projection also influences the ventral striatum, an essential part of the reward system, 79 
with potential modulatory effects on forebrain structures [20] including cingulate and other 80 
parts of the frontal cortex [45]. It should be added that although intranasal delivery of 81 
oxytocin is an easy-to-use and generally well-tolerated approach [46,47], routine use, in 82 
particular in clinical settings, will necessitate some optimizing with regard to absorption 83 
despite degradation by the nasal mucosa (for review see [48]). In this context, the respective 84 
administration mode appears to be relevant considering recent reports that the administration 85 
of nebulized or aerosolized compared to simple spray solutions of oxytocin may permit CNS-86 
specific uptake of the hormone [49,50].  87 
 88 
3. Oxytocin’s impact on cognition and emotion 89 
The role of oxytocin in psychosocial, cognitive and emotional processes has become 90 
increasingly clear in recent years (see ref. [3,51] for reviews). A rapidly growing number of 91 
studies provides evidence that intranasally administered oxytocin enhances empathy [52], the 92 
perception of emotional facial expressions as well as covert attention to happy faces [53–56] 93 
and increases trust in others [2]. Oxytocin also enhances the recognition of emotional states 94 
expressed in body language [57], the formation of social memory contents, respective 95 
memory performance [58,59], and moreover may even promote self-perception [60]. 96 
However, oxytocin’s effects may not be purely beneficial in a social sense since the hormone 97 
can also trigger aggression towards members not belonging to one’s own group (out-group 98 
vs. in-group effects) and increase in-group favoritism [61,62](see [63] for review). Neural 99 
mechanisms behind behavioral effects of oxytocin have been identified in studies using 100 
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functional magnetic resonance imaging (fMRI; see [64] for review). One of the first studies 101 
to examine the effect of oxytocin on neural responses found that the hormone reduces 102 
amygdala activation in response to fear-inducing stimuli [65]. Domes and coworkers [66] 103 
reported amygdala responses to facial stimuli to be suppressed by oxytocin independent of 104 
emotional valence, and suggested that oxytocin is involved in general emotion regulation. In 105 
accordance with this assumption, the impact on amygdala activity of the perception of 106 
emotional (happy and angry) faces, and also of pain, trust and hearing infant laughter [67–70] 107 
turned out to be modulated by oxytocin. In addition, oxytocin affects the activity of 108 
frontocortical areas such as anterior cingulate cortex, orbitofrontal cortex and ventromedial 109 
prefrontal cortex during the observation of emotional faces [67,71]. 110 
Social context is an important modulator of the effects that oxytocin exerts on the 111 
processing of social-emotional stimuli. During exposure to aversive social stimuli amygdala 112 
activity is inhibited by oxytocin whereas insular activity is increased along with functional 113 
coupling to the amygdala [72]. This pattern suggests that oxytocin has anxiogenic effects 114 
when subjects are confronted with (socially) threatening stimuli [73–75] and may support the 115 
formation of memory for social interactions [76]. Fittingly, increases in saliva and, 116 
respectively, plasma concentrations of oxytocin have been found during psychosocial stress 117 
[77] and relational distress [78]. In contrast, oxytocin improves the positive effect of social 118 
support on stress reactions and, in these circumstances, exerts anxiolytic effects [74,76,79]. 119 
Person variables moreover appear to play an important role in the interplay between oxytocin 120 
and the regulation of anxiety and stress [74,80]. 121 
Oxytocin has also been implicated to contribute to memory function. In recent animal 122 
studies, oxytocin was found to protect hippocampus plasticity against stress [81] and to 123 
enhance the formation of hippocampus-dependent memory [82]. The hippocampal formation 124 
is essential for the formation and storage of declarative memory, i.e., memory for facts and 125 
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events that can be consciously recollected [83]. Mice lacking oxytocin display impairments in 126 
social memory function, failing to recognize animals they have been familiarized with [84]. 127 
In contrast, other animal studies suggest oxytocin-induced impairments in memory and 128 
learning [85]. In humans, the peptide has been linked to social recognition, inasmuch as it 129 
strengthens the encoding of facial features [86]. On the other hand, Herzmann and coworkers 130 
[87] found that oxytocin impairs recognition memory for both socially relevant and irrelevant 131 
objects. In related studies, Heinrichs and colleagues [88] observed impaired recall 132 
performance after intranasal oxytocin administration. In a recent review of the effects of 133 
intranasal oxytocin on long-term memory in humans, Brambilla and colleagues [89] therefore 134 
point out that there is a link between oxytocin and memory performance, but that the nature 135 
of this effect and the respective mechanisms are still unclear. It has even been proposed that 136 
the effects of oxytocin on social behavior might be primarily due to its impact on global 137 
cognitive processing capacities, namely improvements in working memory [90].  138 
The psychosocial effects of oxytocin shortly summarized above may be of particular 139 
clinical relevance with a view to psychiatric disorders with a pronounced social component. 140 
Therefore, the clinical potential of oxytocin administration has been investigated with regard 141 
to disorders involving social dysfunction such as autism, social anxiety, borderline 142 
personality disorder and schizophrenia as well as to impairments like post-traumatic stress 143 
disorder (for review see ref. [91]). Respective meta-analyses indicate that improving effects 144 
of oxytocin may be particularly pertinent in autistic persons (see ref. [92] for an overview). 145 
At the same time, there is some concern and discussion about the use of intranasal oxytocin 146 
in behavioral research [93–98], in particular about the efficacy of oxytocin penetration into 147 
the brain after intranasal administration [93]. Walum and colleagues [99] recommend 148 
improving the reliability of human studies using the intranasal administration paradigm. 149 
Publication bias might be an issue, so that better dissemination of oxytocin studies with 150 
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negative results appears desirable [98]. Clearly, a greater number of positive as well as 151 
negative results is needed to understand the complex effects of intranasal oxytocin on human 152 
behavior and to unravel the possible mechanisms behind these effects.  153 
 154 
4. Oxytocin as an anorexigenic neuropeptide 155 
4.1. Oxytocin’s impact on eating behavior and energy homeostasis in animals  156 
Thanks to research efforts in the past two to three decades, the contribution of oxytocin to the 157 
regulation of eating behavior and metabolism has gained increasing attention, and it seems 158 
like oxytocin is now not only recognized as a social peptide, but also as a messenger with 159 
relevance for food intake control. First hints at a role of oxytocin in the regulation of food 160 
intake came from animal studies where lesions of the oxytocin-expressing hypothalamic PVN 161 
resulted in increases in food intake and body weight [100,101]. In 1989, Arletti and 162 
colleagues [102] demonstrated that intraperitoneal (IP) and intracerebroventricular (ICV) 163 
injection of oxytocin decreases chow intake in male rats one hour after administration. 164 
Further experiments indicated that ICV administration of oxytocin reduces food intake in 165 
normal-weight rats [7]. Importantly, animals with genetically or diet-induced obesity (DIO) 166 
also respond to oxytocin administration. Thus, IP and subcutaneous (SC) injection of 167 
oxytocin suppresses food intake and SC injection reduces fat mass in DIO mice [8], and also 168 
improves insulin sensitivity [103]. In ob/ob mice, two weeks of SC oxytocin administration 169 
led to a reduction in food intake and body weight [104]. In obese Zucker-fatty rats [105] and 170 
obese diabetic db/db mice [106], ICV and, respectively, IP oxytocin administration also 171 
produced anorexigenic effects. Fittingly, twelve weeks of SC oxytocin administration via 172 
osmotic pumps improved glucose metabolism and reduced body fat content in db/db mice 173 
[107]. Corresponding anti-obesity effects of oxytocin were found in DIO rats [12,108]. 174 
Notably, oxytocin- or OXTR-deficient mice display modest, late-onset obesity in the absence 175 
12 
 
of changes in food intake behavior [109,110], and in some experiments oxytocin did not alter 176 
energy intake but still  improved energy homeostasis by increasing lipolysis [108]. Enhancing 177 
effects on energy expenditure have moreover been observed to mediate some of the catabolic 178 
impact of oxytocin [9,12,13,111]. Thus, the beneficial effect of oxytocin on body weight 179 
regulation as derived from animal studies is clearly not limited to reductions in food intake.    180 
The inhibitory effect of oxytocin on food intake has been attributed to different 181 
mechanisms in which the peptide appears to be involved, varying between homeostatic and 182 
more reward-related, hedonic processes. Oxytocin delays gastric emptying [35], while gastric 183 
distention activates oxytocin release [112]. In addition, oxytocin has been found to influence 184 
food selection [113,114] (see ref. [115] for review). Animal studies moreover suggest that 185 
oxytocin in particular decreases carbohydrate intake. Oxytocin-knockout mice display 186 
increased intake of sucrose [116] and also increased carbohydrate intake in general, i.e., 187 
independent of sweet taste [113]. Vice versa, injection of oxytocin into the VTA suppresses 188 
sucrose intake [117]. Experiments distinguishing between the sweet and the fatty component 189 
of palatable food show that oxytocin deficiency seems to affect carbohydrate rather than fat 190 
consumption [114,118]. However, comprehensive research by the group of Blevins [119] 191 
indicates that long-term third ventricular oxytocin infusion also affects fat consumption and 192 
fat oxidation: in rats kept on a high-fat diet, oxytocin curbed calorie consumption and 193 
decreased body weight gain relative to controls, effects that were not observed when the rats 194 
were on a chow-diet. Importantly, oxytocin also reduced energy intake and prevented weight 195 
gain in animals on a sucrose-free high-fat diet. In sum, these experiments indicated that 196 
oxytocin maintains energy expenditure despite concurrent weight loss, increases fat oxidation 197 
and may boost CCK-mediated satiety responses [11]. The ability of oxytocin to sensitize 198 
satiety centers in the hindbrain to the effects of CCK can be assumed to play a role in this 199 
context [6]. 200 
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The anorexigenic role of oxytocin has been proposed to rely at least in part on the 201 
downstream mediation of the effects of leptin [120], a hormone produced in white fat cells 202 
that provides the CNS with feedback on the amount of energy stored as body fat and 203 
therefore is one of the major signals establishing energy balance [121]. Blevins and 204 
coworkers demonstrated in rats that oxytocin-expressing neurons in the hypothalamic PVN 205 
contribute to the inhibitory impact of leptin on food intake [5]. Wu and coworkers [13] found 206 
no effect of adult ablation of oxytocin neurons on body weight, food intake and energy 207 
expenditure in mice on a regular diet; still, the mice lacking oxytocin neurons showed a 208 
reduced response to the anorexigenic effect of leptin and were more prone to develop DIO 209 
due to reduced energy expenditure. Hypothalamic oxytocinergic neurons project to structures 210 
of the brain reward circuit such as the NAcc [122],
 
and oxytocin administration attenuates 211 
dopamine signaling in the NAcc as well as the striatum [123], which suggests that the peptide 212 
may also inhibit eating behavior by modulating the reward-related, ‘hedonic’ effect of eating 213 
(see also next paragraph).   214 
4.2. Oxytocin’s impact on the control of food intake in healthy humans 215 
Studies in humans on the effects of oxytocin on eating behavior are still rare. Early studies 216 
failed to demonstrate an effect of peripheral administration of oxytocin on food intake [124], 217 
which is not surprising since, as stated above, only a small percentage of oxytocin 218 
(presumably around 0.005%) may cross the blood-brain barrier to bind to oxytocin receptors 219 
in the CNS [21]. However, the results of more recent studies relying on the intranasal 220 
administration of oxytocin have yielded first evidence for a hypophagic effect of the peptide. 221 
The first study addressing the impact of intranasal oxytocin on food intake investigated if the 222 
peptide reduces hunger- and reward-driven food intake in normal-weight healthy men [14]. It 223 
turned out that oxytocin strongly decreased the consumption of chocolate cookies assessed 224 
around three hours after peptide administration and 90 min after ad-libitum breakfast intake, 225 
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i.e., at a time-point when reward-related eating motivation prevailed. In contrast, hunger-226 
driven breakfast intake in the fasted state was not affected by oxytocin [14]. In that study, in 227 
accordance with experiments in humans [79] and animals [12,108], intranasal oxytocin also 228 
suppressed endocrine stress axis activity and curbed the postprandial peak in plasma glucose 229 
concentrations. Beneficial effects on glucose homeostasis were corroborated in experiments 230 
in healthy men who underwent an oral glucose tolerance test [125]. Here, oxytocin attenuated 231 
peak excursions of plasma glucose and augmented early increases in insulin and C-peptide 232 
concentrations, results that according to oral minimal model analyses indicated a pronounced 233 
oxytocin-induced increase in β-cell responsivity and a more than twofold improvement in 234 
glucose tolerance. When the impact of oxytocin on eating behavior was compared between 235 
normal-weight and obese subjects [16], cookie intake turned out to be likewise reduced by 236 
oxytocin and the peptide induced comparable changes in stress hormone- and glucose 237 
homeostasis-related blood parameters in obese participants. Remarkably, obese individuals in 238 
addition decreased hunger-driven breakfast intake after oxytocin administration, i.e., 239 
displayed a hypophagic effect that was absent in normal-weight humans. However, oxytocin-240 
induced reductions in hunger-driven food intake from a breakfast buffet were found in obese, 241 
but also normal-weight participants in related studies [15], which moreover indicated that the 242 
anorexigenic effect centered on fat intake (before correction for multiple comparisons). These 243 
results were accompanied by an oxytocin-induced increase in circulating CCK concentrations 244 
that, as the authors report, were not related to changes in calorie intake, and signs of 245 
improved insulin sensitivity after administration of the peptide.  246 
It is to note in this context that oxytocin and dopamine signaling have been found in 247 
humans [126] and animals [127] to interact in the regulation of pair bonding, and that 248 
intranasal oxytocin administered to nulliparous and postpartum women (at the dose also used 249 
in food-related experiments [14–16]) increases VTA activation during exposure to images of 250 
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crying infants as well as sexual stimuli [128]. Likewise, oxytocin enhances VTA activation in 251 
response to cues that signal social reward or punishment, although this effect is modulated by 252 
intraindividual differences in sociability [129]. Moreover, variability in the oxytocin gene 253 
explains interindividual differences in dopaminergic responses to stress measured by positron 254 
emission tomography [130]. These findings support the tentative assumption that oxytocin 255 
exerts some of its effects on food intake in humans by acting on reward processing, although 256 
at the moment it remains to be seen if the effect of oxytocin on eating behavior is primarily 257 
hunger- or reward-driven.  258 
There is some first evidence that in addition to acting via homeostatic and reward-259 
related mechanisms, oxytocin also reduces food intake by enhancing cognitive control 260 
mechanisms. Thus, a recent neuroimaging study [131] revealed that oxytocin reduces craving 261 
for food and in parallel increases activity of prefrontal cortical areas in women. Clearly, 262 
further studies are needed to pinpoint the exact mechanisms behind the hypophagic effect of 263 
oxytocin in humans. They should also answer the obvious question whether this effect is 264 
conveyed, at least in part, via oxytocin’s contribution to the regulation of psychosocial 265 
functions, so that a strong modulatory role of social context in the extent or even direction of 266 
oxytocin’s effect on eating behavior would be expected (see chapter 5).  267 
4.3 Oxytocin as a potential intervention in eating disorders and obesity 268 
The contribution of oxytocin to the control of food intake as illustrated in studies in animals 269 
and healthy subjects raises the question if oxytocin might support therapeutic interventions 270 
aimed at specific eating disorders. Individuals with anorexia nervosa have been found to 271 
display increased oxytocin concentrations after standardized meal intake [132], suggesting 272 
that changes in oxytocin signaling might be a feature of or even a pathophysiological factor 273 
in this disorder. Accordingly, anorexia has been associated with epigenetic dysregulation of 274 
the OXTR gene [133]. Intranasal oxytocin administration to patients with anorexia nervosa 275 
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changes their attitude towards social and food-related stimuli; the peptide induces a shift from 276 
the avoidance of angry faces towards increased vigilance and moreover attenuated attention 277 
to food stimuli [134,135]. These and related promising findings [136,137] by the group of 278 
Janet Treasure suggest that therapeutic approaches aiming at improving emotional and 279 
eating-related processes in anorectic, and moreover bulimic patients might be supported by 280 
concurrent oxytocin delivery [138], but will need to be corroborated in larger clinical trials. 281 
Of note, irregularities in oxytocin signaling, i.e., an OXTR gene polymorphism, have also 282 
been associated with bulimia nervosa [139].  283 
  Obesity is presumably linked the emergence of central nervous resistance against the 284 
hypophagic effects of the adiposity signals leptin and insulin [121,140]. As mentioned above, 285 
it appears that in some contrast to this pattern the brain of obese animals and humans displays 286 
intact or even enhanced sensitivity to the anorexigenic impact of oxytocin [16,120]. It has 287 
been speculated that the relatively elevated cholesterol levels in obesity may boost high-288 
affinity binding of oxytocin to the OXTR [27,141]. Support for the assumption that oxytocin 289 
signaling is altered in obesity comes from studies linking the OXTR gene to body weight 290 
[142,143] and the observation that overweight subjects as well as newly diagnosed diabetic 291 
patients display lower circulating concentrations of oxytocin when compared to normal-292 
weight controls [144]. Patients with Prader-Willi syndrome, who suffer from hyperphagic 293 
obesity as a consequence of persistent food craving, display a 40% reduction in the number 294 
and size of oxytocin neurons [145]. Pilot experiments in patients with this syndrome who 295 
received oxytocin substitution via the intranasal pathway for eight weeks yielded none of the 296 
intended effects on body weight and psychosocial function, which might have been due to a 297 
lack of feed-forward endogenous oxytocin release after exogenous delivery [146]. In related 298 
studies [147], young children with Prader-Willi syndrome improved their social and food-299 
related behavior after a four-week oxytocin intervention. Taken together, these findings 300 
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suggest that the oxytocin system might be a potential target of clinical interventions to 301 
normalize eating behavior [16,46]. Considering evidence that metabolic disorders increase 302 
the risk of cognitive impairments [148,149] and meta-analyses indicating that weight loss in 303 
subjects with overweight or obesity is associated with respective enhancements [150], the 304 
beneficial metabolic effect of oxytocin may even be associated with improvements in 305 
cognitive processes. 306 
In animal experiments, DIO rhesus monkeys receiving subcutaneous oxytocin for four 307 
weeks reduced their food intake by around 27% and their body weight by 3.3%, while their 308 
energy expenditure increased by 14% [9]. Obese human subjects reduced their food intake by 309 
around 10% in the first hours after acute intranasal administration [16]. When obese 310 
individuals received four daily intranasal doses of 24 IU oxytocin for a duration of eight 311 
weeks, they were observed to lose around 9 kg of body weight and to show a decrease in 312 
waist and hip circumference [103]. Since the interpretation of these results is complicated by 313 
the large pre-administration differences in BMI and age between the treatment and the 314 
control groups (36 vs. 30 kg/m
2
, 29 vs. 41 years), further and possibly larger trials are clearly 315 
needed to sound the potential of oxytocin as an anti-obesity drug. In these studies it will be of 316 
high relevance to address potential sex differences, which are suggested by some experiments 317 
in animals [13], and carefully control for side effects on metabolic parameters but also 318 
psychosocial functions. Although the intranasal administration of oxytocin at doses from 18-319 
40 IU – the range that comprises most doses commonly applied in experimental settings – 320 
does not acutely induce distinguishable side-effects according to meta-analyses [47] chronic 321 
oxytocin administration was associated with detrimental effects on social behavior in a 322 
number of animal studies [151–153]. While it is unclear whether these findings can be 323 
directly translated to the human situation, they pose a certain caveat to respective clinical 324 
trials [154]. 325 
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 326 
5. Oxytocin as a link between psychosocial mechanisms and eating behavior  327 
The findings discussed above open up an interesting new perspective for oxytocin as a 328 
regulator of eating behavior in humans, although the mechanisms underlying oxytocin’s 329 
hypophagic effect are only poorly understood. In particular, it is unknown why oxytocin in 330 
contrast to other satiating messengers is effective in obese humans. It might even be proposed 331 
that the impact of oxytocin on eating behavior is tightly interrelated with or even dependent 332 
on its psychosocial function, so that a specific social setting of food intake could be a 333 
necessary prerequisite for the effects of oxytocin to emerge. Notably, animal experiments 334 
indicate that social cues can modulate the effect of an OXTR antagonist on sucrose intake: 335 
subordinate mice only showed increased sucrose consumption due to OXTR antagonization 336 
when no social cues related to a dominant animal were present [115,155]. It is well-known 337 
that in humans, cognitive factors such as long-term dietary goals [156], social norms [157] 338 
and the context of eating, e.g., time of the day [158], are of paramount relevance for everyday 339 
food intake behavior. They may even override the homeostatic/reward-related control of 340 
ingestion [159]. In particular, the social context of food intake is a strong determinant of how 341 
much is consumed. Meals that are eaten in the company of others are larger than meals eaten 342 
alone [160], and the duration of meals is prolonged when more people are present [161]. The 343 
amount of ingested food also tends to follow the example given by other subjects – regardless 344 
if they are present or respective information is given [162] – but this effect appears to be 345 
triggered only by peers of the same weight status [163]. Obese individuals model their food 346 
intake according to other obese but not to normal-weight subjects [164]. Importantly, the 347 
oxytocin effects on eating behavior found in laboratory studies [14–16] were observed in 348 
people eating alone – albeit under overt or implicit supervision by the experimenters – 349 
whereas in everyday life, most meals are ingested in social settings.  350 
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Considering the involvement of oxytocin in psychosocial function [165], oxytocin’s 351 
effect on food intake in humans might indeed be strongly modulated or even primarily 352 
mediated by “non-physiological” (in the sense of predominantly psychological) factors. This 353 
assumption is supported by studies in chimpanzees where active food sharing increased 354 
urinary oxytocin levels and bonding behavior [166]. Moreover, oxytocin’s attenuating effect 355 
on stress reactivity and food consumption might be argued to converge with its basic 356 
physiological role in pair-bonding and mother-infant-interaction. E.g., the act of 357 
breastfeeding certainly benefits from relative protection against interfering (food-related) 358 
stimuli from the environment. In this regard, social context and interindividual differences as 359 
modulators of psychosocial stress [74] can be expected to interact with the effect of oxytocin 360 
on eating behavior, but to our knowledge, these interactions are yet to be systematically 361 
investigated. Elucidating presumable neuro-psychosocial mechanisms of oxytocin’s 362 
metabolic impact will be an essential step in the assessment of oxytocin’s potential as an 363 
appetite-reducing drug under conditions of day-to-day eating behavior. In clinical contexts, 364 
the involvement of oxytocin in multiple bodily and psychological functions will demand 365 
particular attention because this neuropeptide may also link seemingly unconnected 366 
pathophysiological conditions.  367 
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Figure 1. Schematic overview of oxytocin effects. The role of endogenous (primarily 930 
hypothalamus-derived) oxytocin has been investigated in numerous studies relying 931 
mostly (in the human setting) on intranasal delivery. Oxytocin has been shown to curb 932 
food intake and decrease body weight both in animals and humans (purple arrow). 933 
Effects on metabolism furthermore comprise increases in energy expenditure, lipolysis, 934 
glucose tolerance and insulin sensitivity (green arrow). The psychosocial effect of 935 
oxytocin concerns social, emotional and cognitive functions as well as anxiety- and 936 
stress-related processes (blue arrow). 937 
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